Concepedia

Author

James Brugarolas

The University of Texas Southwestern Medical CenterORCID

Also Known As

Brugarolas, James, Brugarolas, James (James Burfau), 1969-, J Brugarolas, J. Brugarolas, James B Brugarolas, James B. Brugarolas, James Brugarolas, Peña-Llopis, Samuel

578

Publications

17.9K

Citations

63

H-Index

127

Concepts

All Affiliations

The University of Texas Southwestern Medical CenterAdvanced Imaging Research (United States)Southwestern Medical CenterHoward Hughes Medical Institute
JB

About

James Brugarolas is an author at The University of Texas Southwestern Medical Center specializing in medicine, urology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

44

68

9K

2

Health Sciences

8

8

555

3

Engineering

4

4

227

4

Natural Sciences

4

4

626

5

Public Health

1

1

15

James Brugarolas

×

135

Publications

15.3K

Citations

58

H-Index

YearCitations

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

James Brugarolas, Kui Lei, Rebecca L. Hurley,

Genes & Development

2004

1.4K

Radiation-induced cell cycle arrest compromised by p21 deficiency

James Brugarolas, Chitra Chandrasekaran, Jeffrey I. Gordon,

Nature

1995

1.2K

BAP1 loss defines a new class of renal cell carcinoma

Samuel Peña‐Llopis, Silvia Vega-Rubín-de-Celis, Arnold Liao,

Nature Genetics

2012

973

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Pradip K. Majumder, Phillip G. Febbo, Rachel Bikoff,

Nature Medicine

2004

954

Targeting renal cell carcinoma with a HIF-2 antagonist

Wenfang Chen, Haley Hill, Alana Christie,

Nature

2016

697

TSC2 regulates VEGF through mTOR-dependent and -independent pathways

James Brugarolas, Francisca Vázquez, Archana Reddy,

Cancer Cell

2003

525

Regulation of TFEB and V-ATPases by mTORC1

Samuel Peña‐Llopis, Silvia Vega-Rubín-de-Celis, Jacob C. Schwartz,

The EMBO Journal

2011

454

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation

Payal Kapur, Samuel Peña‐Llopis, Alana Christie,

The Lancet Oncology

2013

445

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

Kevin D. Courtney, Jeffrey R. Infante, Elaine T. Lam,

Journal of Clinical Oncology

2017

369

Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes

Steffen Durinck, Eric Stawiski, Andrea Pavía-Jiménez,

Nature Genetics

2014

353

Page 1